Girolamo Pelaia
Girolamo Pelaia is an expert in Pulmonology at Magna Graecia University (Italy). As of October 2026, ScienceLeadR ranks Girolamo Pelaia in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Girolamo Pelaia has authored 255 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 3 of them ongoing. SLR score: 902 (community average: 125). How the SLR is computed.
LeadR Profile
Pulmonology
Subspecialties: Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 255
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Effects of umeclidinium bromide in the management of small airway disease: a pilot study. PMID 42904745 — exercise, pilot projects, pilots, lung, respiratory tract diseases, airway resistance, lung diseases, dyspnea, vital capacity | Monaldi Arch Chest Dis | 2026 | 0 |
| Biologic Use in Type 2 versus Non-Type 2 Asthma: Similarities, Differences, and Challenges. PMID 42899165 — antibodies, adrenal cortex hormones, biomarkers, antibodies, monoclonal, therapeutics, asthma | J Inflamm Res | 2026 | 0 |
| Unmet Needs and New Opportunities in Chronic Obstructive Pulmonary Disease in Italy: A Narrative Review with Insights from the GULP Study. PMID 42831088 — eosinophils, pulmonary disease, chronic obstructive, antibodies, monoclonal, therapeutics, lung diseases, lung diseases, obstructive | Int J Chron Obstruct Pulmon Dis | 2026 | 0 |
| Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms. PMID 42741441 — lung, adrenal cortex hormones, eosinophils, therapeutics, asthma, biological therapy | J Inflamm Res | 2026 | 0 |
| Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders. PMID 42351788 — rhinitis, allergic, allergens, immunotherapy, therapeutics, asthma | Biomedicines | 2026 | 1 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma 2024-515162-13-00 — safety, adrenal cortex hormones, therapeutics, asthma | Phase 3 | Active not recruiting | 2025 |
| Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy NCT05681962 — lung, blood, fibrosis, bronchoalveolar lavage, neoplasms, blood pressure, bronchoscopy, biopsy, respiratory insufficiency, cell biology, lung neoplasms, pulmonary fibrosis, pneumonia, endoscopy, records, lung diseases, ventilation, outpatients, cannula, lung diseases, interstitial, cytology | N/A | Recruiting | 2023 |
| MANI Real life Perspective Observatory NCT04796844 — cohort studies, asthma | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map